122 related articles for article (PubMed ID: 30403991)
1. Elusive Conformational Dynamics of PPARγ Inactivation Tied Down by Chemical Cross-Linking.
Mohr JP; Bruce JE
Structure; 2018 Nov; 26(11):1425-1427. PubMed ID: 30403991
[TBL] [Abstract][Full Text] [Related]
2. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
[TBL] [Abstract][Full Text] [Related]
3. Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma.
Fujimura T; Sakuma H; Ohkubo-Suzuki A; Aramori I; Mutoh S
Biol Pharm Bull; 2006 Mar; 29(3):423-9. PubMed ID: 16508139
[TBL] [Abstract][Full Text] [Related]
4. Co-crystal structure guided array synthesis of PPARgamma inverse agonists.
Trump RP; Cobb JE; Shearer BG; Lambert MH; Nolte RT; Willson TM; Buckholz RG; Zhao SM; Leesnitzer LM; Iannone MA; Pearce KH; Billin AN; Hoekstra WJ
Bioorg Med Chem Lett; 2007 Jul; 17(14):3916-20. PubMed ID: 17533125
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
Jang JY; Bae H; Lee YJ; Choi YI; Kim HJ; Park SB; Suh SW; Kim SW; Han BW
Sci Rep; 2018 Jan; 8(1):31. PubMed ID: 29311579
[TBL] [Abstract][Full Text] [Related]
6. CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands.
Mottin M; Souza PC; Ricci CG; Skaf MS
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025495
[TBL] [Abstract][Full Text] [Related]
7. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.
Dumasia R; Eagle KA; Kline-Rogers E; May N; Cho L; Mukherjee D
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Oct; 5(5):377-86. PubMed ID: 16248830
[TBL] [Abstract][Full Text] [Related]
8. Two steps, one ligand: How PPARγ binds small-molecule agonists.
Siclari JJ; Gardner KH
Structure; 2021 Sep; 29(9):935-936. PubMed ID: 34478635
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
10. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
Tanaka T
Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARγ-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells.
Han EJ; Im CN; Park SH; Moon EY; Hong SH
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e239-48. PubMed ID: 23332223
[TBL] [Abstract][Full Text] [Related]
12. DASH: a novel analysis method for molecular dynamics simulation data. Analysis of ligands of PPAR-gamma.
Salt DW; Hudson BD; Banting L; Ellis MJ; Ford MG
J Med Chem; 2005 May; 48(9):3214-20. PubMed ID: 15857127
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma.
Jung TI; Baek WK; Suh SI; Jang BC; Song DK; Bae JH; Kwon KY; Bae JH; Cha SD; Bae I; Cho CH
Gynecol Oncol; 2005 May; 97(2):365-73. PubMed ID: 15863131
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
Ohashi M; Gamo K; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
[TBL] [Abstract][Full Text] [Related]
15. The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms.
Ray DM; Akbiyik F; Phipps RP
J Immunol; 2006 Oct; 177(8):5068-76. PubMed ID: 17015690
[TBL] [Abstract][Full Text] [Related]
16. Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease.
Sugawara A; Uruno A; Kudo M; Matsuda K; Yang CW; Ito S
Endocr J; 2010; 57(10):847-52. PubMed ID: 20890053
[TBL] [Abstract][Full Text] [Related]
17. Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy.
Khandekar MJ; Banks AS; Laznik-Bogoslavski D; White JP; Choi JH; Kazak L; Lo JC; Cohen P; Wong KK; Kamenecka TM; Griffin PR; Spiegelman BM
Proc Natl Acad Sci U S A; 2018 Jan; 115(3):561-566. PubMed ID: 29295932
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
[TBL] [Abstract][Full Text] [Related]
19. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
Sauer S
Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
[TBL] [Abstract][Full Text] [Related]
20. Anti-leukemic effects of PPARγ ligands.
Ryu S; Kim DS; Lee MW; Lee JW; Sung KW; Koo HH; Yoo KH
Cancer Lett; 2018 Apr; 418():10-19. PubMed ID: 29331412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
